Atara Biotherapeutics, Inc. (ATRA) Reaches $28.25 52-Week High; Natural Grocers By Vitamin Cottage (NGVC)’s Sentiment Is 1.37

January 14, 2018 - By Vivian Currie

The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) hit a new 52-week high and has $29.38 target or 4.00% above today’s $28.25 share price. The 7 months bullish chart indicates low risk for the $864.33M company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $29.38 price target is reached, the company will be worth $34.57M more. The stock increased 27.54% or $6.1 during the last trading session, reaching $28.25. About 3.69M shares traded or 708.01% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since January 14, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Natural Grocers by Vitamin Cottage, Inc., together with its subsidiaries, operates natural and organic groceries, and dietary supplement retail stores in the United States. The company has market cap of $186.16 million. The Company’s stores offer natural and organic grocery products, such as organic produce; bulk food and private label products; dry, frozen, and canned groceries; meat and seafood products; dairy products, dairy substitutes, and eggs; prepared foods; bread and baked products; and beverages. It has a 27.13 P/E ratio. The companyÂ’s stores also provide private label dietary supplements; body care products comprising cosmetics, skin care, hair care, fragrance, and personal care products containing natural and organic ingredients; pet care and food products; household and general merchandise, including cleaning supplies, paper products, dish and laundry soap, and other common household products; and books and handouts.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 earnings per share, down 80.95% or $0.51 from last year’s $-0.63 per share. After $-1.02 actual earnings per share reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Since August 10, 2017, it had 0 insider buys, and 14 sales for $999,963 activity. $64,438 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by Ciechanover Isaac E.. MCGRATH JOHN also sold $60,102 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. Shares for $43,291 were sold by Clark Mitchall G. on Tuesday, August 15. On Friday, September 15 the insider Haqq Christopher sold $91,800. Shares for $16,931 were sold by Gallagher Carol Giltner. Soffer Gad sold 9,464 shares worth $140,802.

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.26, from 1.28 in 2017Q2. It is positive, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. Bank & Trust Of Montreal Can reported 4,591 shares stake. Blackrock reported 1.99 million shares. Invesco, Georgia-based fund reported 18,791 shares. Royal Retail Bank Of Canada stated it has 2,264 shares. Goldman Sachs Group accumulated 0% or 19,956 shares. Tower Research Cap Ltd Llc (Trc) owns 1,253 shares or 0% of their US portfolio. Tiaa Cref Inv Management Llc reported 63,812 shares. Nationwide Fund Advsrs accumulated 0% or 13,467 shares. Voya Invest Lc has 11,813 shares for 0% of their portfolio. Northern owns 286,973 shares. Rhumbline Advisers accumulated 31,598 shares. Alps Advisors reported 30,095 shares. Essex Investment Com Limited Com has invested 0.06% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Ameritas Prtnrs holds 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 1,810 shares. The New York-based Metropolitan Life Ny has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Atara Biotherapeutics has $80 highest and $8 lowest target. $27.60’s average target is -2.30% below currents $28.25 stock price. Atara Biotherapeutics had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Sell” rating by Citigroup given on Tuesday, December 15. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Thursday, June 22 by Jefferies. On Friday, September 25 the stock rating was initiated by JMP Securities with “Mkt Perform”. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The firm has “Buy” rating by Jefferies given on Monday, October 24. On Thursday, September 15 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Outperform” rating given on Friday, October 9 by William Blair. Canaccord Genuity initiated it with “Buy” rating and $80 target in Wednesday, September 9 report. Jefferies maintained it with “Buy” rating and $30.0 target in Thursday, August 31 report. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, November 18 report.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $864.33 million. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $553,219 activity.

Ratings analysis reveals 25% of Natural Grocers’s analysts are positive. Out of 4 Wall Street analysts rating Natural Grocers, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. NGVC was included in 4 notes of analysts from September 23, 2016. Barclays Capital initiated the stock with “Equal Weight” rating in Friday, September 23 report. As per Tuesday, January 31, the company rating was downgraded by Jefferies. On Tuesday, October 11 the stock rating was initiated by Citigroup with “Buy”. The stock of Natural Grocers by Vitamin Cottage, Inc. (NYSE:NGVC) has “Hold” rating given on Friday, February 3 by SunTrust.

The stock decreased 1.07% or $0.09 during the last trading session, reaching $8.33. About 59,307 shares traded. Natural Grocers by Vitamin Cottage, Inc. (NGVC) has declined 26.55% since January 14, 2017 and is downtrending. It has underperformed by 43.25% the S&P500.

Analysts await Natural Grocers by Vitamin Cottage, Inc. (NYSE:NGVC) to report earnings on February, 1. They expect $0.07 EPS, down 22.22% or $0.02 from last year’s $0.09 per share. NGVC’s profit will be $1.56 million for 29.75 P/E if the $0.07 EPS becomes a reality. After $0.06 actual EPS reported by Natural Grocers by Vitamin Cottage, Inc. for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Quantum Capital Management holds 0.25% of its portfolio in Natural Grocers by Vitamin Cottage, Inc. for 186,376 shares. Rutabaga Capital Management Llc Ma owns 182,901 shares or 0.22% of their US portfolio. Moreover, River Road Asset Management Llc has 0.07% invested in the company for 645,577 shares. The California-based Rice Hall James & Associates Llc has invested 0.04% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 66,200 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts